Trial Profile

COG ACNS0331 (CINJ 110417): A Study Evaluating Limited Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Lomustine (Primary) ; Vincristine (Primary)
Indications Medulloblastoma
Focus Therapeutic Use

25 Feb 2021 Biomarkers information updated
19 Jan 2013 Planned number of patients changed from 510 to 554 as reported by M.D. Anderson Cancer Center record.
07 Dec 2012 New source identified and integrated (Mayo Clinic)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com